Lupin ties up with Sandoz to commercialise biosimilar product

Lupin and Sandoz sign licensing deal for biosimilar ranibizumab across multiple regions

Sandoz will oversee commercialization of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia under the terms of the agreement.

Lupin announces licensing deal for Ranibizumab biosimilar - Express Pharma

Lupin announced it has entered into an agreement with Switzerland-based Sandoz Group AG to market and commercialise Lupin’s biosimilar ranibizumab across multiple regions. Under the agreement, Sandoz will manage commercialisation of the product in the European Union, excluding Germany, as well as Switzerland, Norway, Australia, Hong Kong, Vietnam and Malaysia. Lupin will be responsible for manufacturing the product and handling regulatory submis…

Lupin ties up with Sandoz to commercialise biosimilar product

New Delhi, Aug 12 (PTI) Drug firm Lupin on Tuesday said it has partnered with Switzerland-based Sandoz Group AG to commercialise its biosimilar ranibizumab across multiple regions.Under the terms of the agreement, Sandoz will oversee commercialisation of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia, the Mumbai-based drug maker said in a statement.Lupin will be respons…

Lupin Announces Licensing Deal for Ranibizumab Biosimilar